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Abstract
Early in the pathological process of osteoarthritis (OA),
subchondral bone remodelling, which is related to altered
osteoblast metabolism, takes place. In the present study, we
explored in human OA subchondral bone whether chondroitin
sulfate (CS), glucosamine sulfate (GS), or both together affect
the major bone biomarkers, osteoprotegerin (OPG), receptor
activator of nuclear factor-kappa B ligand (RANKL), and the pro-
resorptive activity of OA osteoblasts. The effect of CS (200 μg/
mL), GS (50 and 200 μg/mL), or both together on human OA
subchondral bone osteoblasts, in the presence or absence of
1,25(OH)2D3 (vitamin D3) (50 nM), was determined on the bone
biomarkers alkaline phosphatase and osteocalcin, on the
expression (mRNA) and production (enzyme-linked
immunosorbent assay) of bone remodelling factors OPG and
RANKL, and on the pro-resorptive activity of these cells. For the
latter experiments, human OA osteoblasts were incubated with
differentiated peripheral blood mononuclear cells on a sub-
micron synthetic calcium phosphate thin film. Data showed that
CS and GS affected neither basal nor vitamin D3-induced
alkaline phosphatase or osteocalcin release. Interestingly, OPG
expression and production under basal conditions or vitamin D3
treatment were upregulated by CS and by both CS and GS
incubated together. Under basal conditions, RANKL expression
was significantly reduced by CS and by both drugs incubated
together. Under vitamin D3, these drugs also showed a
decrease in RANKL  level, which, however, did not reach
statistical significance. Importantly, under basal conditions, CS
and both compounds combined significantly upregulated the
expression ratio of OPG/RANKL. Vitamin D3 decreased this
ratio, and GS further decreased it. Both drugs reduced the
resorption activity, and statistical significance was reached for
GS and when CS and GS were incubated together. Our data
indicate that CS and GS do not overly affect cell integrity or
bone biomarkers. Yet CS and both compounds together
increase the expression ratio of OPG/RANKL, suggesting a
positive effect on OA subchondral bone structural changes. This
was confirmed by the decreased resorptive activity for the
combination of CS and GS. These data are of major significance
and may help to explain how these two drugs exert a positive
effect on OA pathophysiology.
Introduction
Osteoarthritis (OA) is one of the most common joint disorders,
affecting approximately 65% of individuals over 60 years of
age, many of whom suffer from pain and functional disability,
and resulting in a significant social and economic burden.
Despite the high prevalence of OA, its precise
etiopathogenesis is not yet completely understood, although
significant progress has been made in the last few decades.
CS = chondroitin sulfate; CT = threshold cycle; DMEM = Dulbecco's modified Eagle's medium; EIA = enzyme immunoassay; FCS = fetal calf serum; 
GAG = glycosaminoglycan; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; GS = glucosamine sulfate; H-OA = high-osteoarthritis; IL-1β = 
interleukin-1-beta; L-OA = low-osteoarthritis; M-CSF = macrophage colony-stimulating factor; OA = osteoarthritis; OPG = osteoprotegerin; PBMC 
= peripheral blood mononuclear cell; PCR = polymerase chain reaction; PGE2 = prostaglandin E2; RANKL = receptor activator of nuclear factor-
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OA is considered a complex illness in which tissues of the
joint, including cartilage, synovial membrane, and subchondral
bone, play significant roles [1]. Even though articular cartilage
destruction is a major characteristic of OA, we still do not com-
pletely understand what initiates its degradation and loss. Syn-
ovial membrane inflammation is believed to play an important
role in the progression of joint tissue lesions; however, there is
a general consensus that synovial inflammation in OA is not
the primary cause of the disease but rather a secondary phe-
nomenon related to multiple factors, including cartilage matrix
degradation. Moreover, studies have also demonstrated that,
in OA, the subchondral bone is not an innocent bystander but
is the site of several dynamic morphological changes that
appear to be part of the disease process [2]. These changes
are associated with a number of local abnormal biochemical
pathways related to the altered osteoblast metabolism.
Some compounds have been shown to have a slow-acting
symptomatic effect in OA and are termed SYSADOA [3].
Among this group of pharmacological substances are chon-
droitin sulfate (CS and glucosamine sulfate (GS). Several
strategies have been investigated for the symptomatic and
structural management of OA using these two drugs. There is
compelling evidence of the potential for inhibiting the struc-
tural progression of OA with CS and GS in patients with OA
of the knees and hands [4-6] Moreover, the recent Glu-
cosamine/Chondroitin Arthritis Intervention Trial suggests, fol-
lowing exploratory analyses, that the combination of the two
drugs was effective on symptoms in OA patients having mod-
erate to severe knee pain [7].
Glucosamine is an aminosaccharide that acts as a preferred
substrate for the biosynthesis of glycosaminoglycan (GAG
chains and, subsequently, for the production of aggrecan and
other proteoglycans. CS is a major component of the extracel-
lular matrix of many connective tissues, including cartilage,
bone, skin, ligaments, and tendons. It is a sulfated GAG com-
posed of a long unbranched polysaccharide chain with a
repeating disaccharide structure of N-acetylgalactosamine
and glucuronic acid. Most of the N-acetylgalactosamine resi-
dues are sulfated, particularly in the 4- or 6-position, making it
a strongly charged polyanion. A number of small leucine-rich
proteoglycans, especially decorin and biglycan (which contain
high levels of CS chains), are present in the bone extracellular
matrix compartment [8]. In OA articular tissues, changes in the
structure of CS have been reported, with the appearance of
longer chains [9]. In in vitro studies, both GS and CS have
demonstrated the ability to diminish pro-inflammatory factors,
to modify the cellular death process, and to improve the anab-
olism/catabolism balance of extracellular cartilage matrix. In
addition, CS has proven to have a positive effect on OA syno-
vial membrane. However, the exact mechanisms of action
underlying their beneficial effects remain poorly understood,
and their action on the factors involved in subchondral bone
remodelling has never been investigated.
Although sclerosis of the subchondral bone is seen at a late
stage of the OA process, several in vitro and in vivo [10]
reports have indicated that subchondral bone remodelling
involving bone resorption occurs early in the disease. Osteob-
lasts from human OA subchondral bone have been shown to
produce an excess of many biochemical factors favoring the
maturation/activation of osteoclasts and/or resorption of bone
matrix. Abnormal levels of two major factors that play a major
role in bone resorption, osteoprotegerin (OPG) and the recep-
tor activator of nuclear factor-kappa B ligand (RANKL), have
been found in human OA subchondral bone osteoblasts [11].
Both factors are synthesized by osteoblasts, and RANKL, a
member of the tumour necrosis factor superfamily, is an essen-
tial cytokine for osteoclast differentiation and bone loss. On
the other hand, OPG is considered a decoy receptor that
blocks the binding of RANKL to the RANK receptor, located
on osteoclast precursors, thereby inhibiting the terminal stage
of osteoclastic differentiation and suppressing its activation as
well as inducing the apoptosis of mature osteoclasts. Thus,
OPG, by preventing osteoclastogenesis, inhibits bone
resorption.
Recent data showed that human OA subchondral bone oste-
oblasts could be discriminated into two groups according to
low (L) or high (H) OA osteoblasts based on the level of pros-
taglandin E2 (PGE2 production [12,13].(Interestingly, we fur-
ther showed that L-OA osteoblasts promote osteoclast
differentiation and formation and an increase in RANKL levels
leading to a decreased OPG/RANKL expression ratio in favor
of bone destruction [11]. However, the H-OA osteoblasts
appear to be under the influence of factors favoring bone dep-
osition [11,14].
In the present study, we explored in human subchondral bone
whether CS and GS or both together affect certain bone
biomarkers, OPG and RANKL levels, and pro-resorptive activ-
ity. Data showed that neither CS nor GS overly affects cell
integrity or osteoblast phenotypic cell markers. However, CS
and both CS and GS together significantly increased the
expression ratio of OPG/RANKL, and GS and both CS and
GS significantly decreased the OA osteoblast pro-resorptive
activity. This suggests that these drugs could have a positive
effect on OA subchondral bone structural changes, explaining
the in vivo beneficial effect of CS and GS alone or combined.
Materials and methods
Specimen selection
Human OA specimens were obtained from the femoral con-
dyles of patients undergoing total knee arthroplasty (mean age
± standard deviation: 74 ± 9 years). All patients were evalu-
ated as having OA according to the American College of
Rheumatology clinical criteria [15]. At the time of surgery, the
patients had symptomatic disease requiring medical treatment
in the form of acetaminophen, nonsteroidal anti-inflammatory
drugs, or selective cyclooxygenase-2 inhibitors. None hadAvailable online http://arthritis-research.com/content/9/6/R117
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received intra-articular steroid injections within 3 months prior
to surgery, and none had received medication that would inter-
fere with bone metabolism. The institutional ethics committee
board of Notre-Dame Hospital (Montreal, QC, Canada)
approved the use of the human articular tissues.
Subchondral bone osteoblast culture
The subchondral bone osteoblast culture was prepared as
previously described [16,17] The overlying cartilage was
removed and the trabecular bone tissue was dissected from
the subchondral bone plate. All manipulations were performed
under a magnifying microscope to ensure complete removal of
cartilage and trabecular bone. Briefly, bone samples were cut
into small pieces prior to sequential digestion in the presence
of collagenase type I in BGJb medium (both from Sigma-
Aldrich, Oakville, ON, Canada) without serum at 37°C in a
humidified atmosphere of 5% CO2/95% air. After a 4-hour
incubation period, the bone pieces were cultured in BGJb
medium containing 20% heat-inactivated fetal calf serum
(FCS) (Gibco-BRL, now part of Invitrogen Corporation,
Carlsbad, CA, USA) and an antibiotic mixture (100 units/mL
penicillin base and 100 μg/mL streptomycin base; Invitrogen
Corporation) at 37°C in the humidified atmosphere. This
medium was replaced every 2 days until cells were observed
in the Petri dishes. At this point, the culture medium was
replaced with fresh medium containing 10% FCS until conflu-
ence. Osteoblasts were passaged once and grown until con-
fluence (about 5 days) in Dulbecco's modified Eagle's medium
(DMEM) containing 10% FCS. Of note, osteoblasts from
human subchondral bone, as prepared, have been shown to
be mature differentiated cells since they express the bone-
specific markers, including alkaline phosphatase and osteo-
calcin [12,13,16-21].
Cells were seeded at high density (200,000 cells/12 wells per
plate) and cultured to confluence. They were treated with CS,
GS, or both together in the absence or presence of
1,25(OH)2D3 (vitamin D3). The concentrations used were 200
μg/mL for CS (CS Bio-Active; Bioiberica, S.A., Barcelona,
Spain), 50 and 200 μg/mL for GS (Bioiberica, S.A.), 200 μg/
mL for CS and GS when used together, and 50 nM for vitamin
D3 (Sigma-Aldrich). The effect of the factors was assessed by
pre-incubating confluent cells in DMEM (Invitrogen Corpora-
tion)/0.5% FCS for 24 hours followed by an incubation of 18
hours (for mRNA determination) and 48 hours (for protein
determination) with the factors under study. Preliminary exper-
iments in which time course (0, 2, 8, 18, and 36 hours) was
performed for the expression of OPG and RANKL under CS
and GS treatment revealed a maximum effect on both OPG
and RANKL at 18 hours.
RNA extraction, reverse transcription, and real-time 
polymerase chain reaction
Total cellular RNA from human osteoblasts was extracted with
the TRIzol™ reagent (Invitrogen Corporation) according to the
manufacturer's specifications and treated with the DNA-free™
DNase Treatment and Removal kit (Ambion, Inc., Austin, TX,
USA) to ensure complete removal of chromosomal DNA. The
RNA was quantitated using the RiboGreen RNA quantitation
kit (Molecular Probes Inc., now part of Invitrogen Corporation).
The reverse transcription (RT) reactions were primed with ran-
dom hexamers as described previously [22]. Real-time quanti-
tation of mRNA was performed as previously described [22] in
the GeneAmp 5700 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) with the 2× Quantitect
SYBR Green PCR [polymerase chain reaction] Master Mix
(Qiagen, Mississauga, ON, Canada) used according to the
manufacturer's specifications. In brief, 45 ng of the cDNA
obtained from the RT reactions was amplified in a total volume
of 50 μL consisting of 1× Master mix, uracil-N-glycosylase
(Epicentre Biotechnologies, Madison, WI, USA) 0.5 units, and
the gene-specific primers, which were added at a final concen-
tration of 200 nM. The primer sequences were 5'-GTT-
TACTTTGGTGCCAGG (antisense) and 5'-
GCTTGAAACATAGGAGCTG (sense) (OPG), 5'-GGGTAT-
GAGAACTTGGGATT (antisense) and 5'-CACTATTAAT-
GCCACCGAC (sense) (RANKL), and 5'-
CAGAACATCATCCCTGCCTCT (antisense) and 5'-GCTT-
GACAAAGTGGTCGTTGAG (sense) (glyceraldehyde-3-
phosphate dehydrogenase [GAPDH]). The primer efficiencies
for the test genes were the same as for the GAPDH gene. The
standard curves were generated with the same plasmids as
the target sequences. The data were collected and processed
with GeneAmp 5700 SDS software and given as a threshold
cycle (CT) corresponding to the PCR cycle at which an
increase in reporter fluorescence above a baseline signal can
first be detected. The CT was then converted to number of
molecules, and the values for each sample were calculated as
the ratio of the number of molecules of the target gene to the
number of molecules of GAPDH. Data are expressed as arbi-
trary unit over the control, which was given 1 as unit.
Protein determinations
As previously described in the literature [12,13,16,17,23,24],
the activity of alkaline phosphatase, osteocalcin, and PGE2
was determined after a 48-hour incubation. The alkaline phos-
phatase was determined in cell lysate, and the levels of osteo-
calcin, OPG, and PGE2  in the culture media. Alkaline
phosphatase activity was determined by substrate hydrolysis
using p-nitrophenylphosphate [16], osteocalcin using an
enzyme immunoassay (EIA) (Biomedical Technologies Inc.,
Stoughton, MA, USA) with a sensitivity of 0.5 ng/mL, OPG by
an enzyme-linked immunosorbent assay (MediCorp Inc., Mon-
treal, QC, Canada) with a sensitivity of 2.8 pg/mL, total soluble
RANKL by an EIA (ALPCO Diagnostics, Salem, NH, USA)
with a sensitivity of 30 pg/mL, and PGE2 by an EIA (Cayman
Chemical Company, Ann Arbor, MI, USA) with a sensitivity of
7.8 pg/mL. The protein concentration was determined using
the bicinchoninic acid method (Pierce, Rockford, IL, USA). AllArthritis Research & Therapy    Vol 9 No 6    Tat et al.
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determinations were performed in duplicate for each cell
culture.
Resorption activity determination
The BD BioCoat Osteologic Bone Cell Culture System (BD
Biosciences, Oakville, ON, Canada) was used. Briefly, this
methodology consists of sub-micron synthetic calcium phos-
phate thin films coated onto culture vessels. In brief, human
peripheral blood mononuclear cells (PBMCs) (100,000 cells/
well) were inoculated onto the wells with culture media con-
taining DMEM/10% FCS, antibiotics, and 25 ng/mL macro-
phage colony-stimulating factor (M-CSF) and incubated for 3
days at 37°C in a humidified atmosphere in order to induce
pre-osteoclastic differentiation [25]. Human OA subchondral
bone osteoblasts (10,000 cells/well) were then inoculated
with the differentiated PBMCs (pre-osteoclast) and incubated
for another 3 days in fresh culture medium. At the end of this
period, culture medium was eliminated and cells were incu-
bated in DMEM containing M-CSF, 10% FCS, and antibiotics
for 3 weeks with factors under testing. Media were changed
every 3 days. Incubation was carried out at 37°C. At the end
of the incubation period, cells were bleached (6% NaOCl,
5.2% NaCl) and extensively washed in sterilized water. Von
Kossa stain was used for contrast as described by BD Bio-
sciences. In brief, the films were stained with fresh silver nitrate
(5%) for 10 minutes and washed extensively, and stains were
developed with fresh sodium carbonate (5%) in formalin
(25%) for approximately 30 seconds. The films were washed
again and fixed with sodium thiosulfate (5%) for 2 minutes and
washed. The quantitation was performed with the use of a light
microscope with the Bioquant software (Bioquant Osteo II, v
8.00.20; BIOQUANT Image Analysis Corporation, Nashville,
TN, USA). Results are represented as the mean resorbed sur-
face per total surface.
To rule out that CS or GS directly affects PBMC differentiation
in osteoclasts, experiments were performed as above with the
PBMCs only, and also with osteoblasts, and the number of dif-
ferentiated osteoclasts was measured with the tartrate-resist-
ant acid phosphatase (TRAP) using the Bioquant software. At
the end of the incubation period, the cells were fixed and
stained for TRAP according to the manufacturer's recommen-
dation (Sigma-Aldrich).
Statistical analysis
Data are expressed as the mean ± standard error of the mean.
Statistical significance was assessed by a two-tailed paired
Student t test. P values of less than 0.05 were considered
significant.
Results
Human osteoarthritis subchondral bone osteoblast 
classification
We previously showed that patients with OA can be discrimi-
nated into two groups classified according to L- or H-OA oste-
oblasts based on the level of PGE2 production [12,13] and
that L-OA osteoblasts (PGE2 levels of less than 2,000 pg/mg
protein) were suggested to favor pro-resorptive activity
whereas the H-OA osteoblasts favor bone deposition [11,14]
To investigate the effects of the compounds on (among other
things) the OPG, RANKL, and pro-resorptive activity levels, we
chose to perform this study with the L-OA osteoblast speci-
mens. In this study, the OA subchondral bone osteoblasts
used had a PGE2 level of 563.4 ± 115.0 pg/mg protein.
Osteoblast biomarkers
Previous studies with human OA subchondral osteoblasts
have shown that these cells have abnormal bone biomarker
levels [12,13,16,17](In this study, we first looked at two such
biomarkers, namely alkaline phosphatase and osteocalcin.
Data showed (Figure 1a,b) that alkaline phosphatase activity
and osteocalcin responded to vitamin D3, as is expected from
human subchondral bone osteoblasts, with approximately 1.5-
and 8-fold increases for alkaline phosphatase and osteocalcin,
respectively, over basal values. Neither alkaline phosphatase
nor osteocalcin was truly affected by CS or GS alone or
together; this is true for both basal conditions and hormonal
stimulation. There was a tendency for all treated specimens to
show higher levels of vitamin D3-induced osteocalcin release,
yet this failed to reach statistical significance (Figure 1b).
Osteoprotegerin and RANKL expression and synthesis
OPG expression (Figure 2a) was not altered by treatment with
vitamin D3. Under basal conditions, OPG  expression was
found to be significantly increased when CS and GS were
incubated together. CS showed an increased level of OPG
expression under either basal conditions (slight) or vitamin D3
induction (p < 0.06). Interestingly, in the presence of vitamin
D3, CS upregulated OPG expression to a level similar to the
one obtained upon treatment with both drugs.
Data from the protein level were almost identical to those from
the  OPG  expression, but CS significantly increased OPG
under both basal and vitamin D3 conditions (Figure 2a). GS
had no true effect on OPG protein either alone or in combina-
tion with vitamin D3. The significantly increased levels of OPG
with CS and GS incubated together appeared to result from
the effect of the CS.
The  RANKL  expression level (Figure 2b) was significantly
decreased with CS and with the combination of the two drugs.
This decrease again appeared to be the result of the CS
effect, as GS upregulated the expression level of RANKL at
the highest concentration. Vitamin D3 drastically upregulated
RANKL  expression. Under this condition, CS alone and in
combination with GS tended to downregulate the RANKL
level. As for OPG, similar values were obtained for CS alone
or combined with GS, again suggesting that the effect is
related to the CS.Available online http://arthritis-research.com/content/9/6/R117
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Although we used a specific EIA to determine the total protein
level of the RANKL, either in the culture medium or in the cell
lysate, the values obtained were at the limit of detection. This
is not surprising as, in order to be able to detect quantifiable
amounts of RANKL in the culture medium with these human
cells and with the available detection EIA, the cells have to be
treated with factors such as pro-inflammatory cytokines[26].
The OPG/RANKL ratio therefore was determined only from
the expression of these factors. However, as the protein levels
of OPG correspond to its expression levels, one would expect
the ratio calculated with the protein to be similar. Data showed
(Figure 2c) that, under basal conditions, the expression ratio of
OPG/RANKL  was significantly increased when cells were
incubated with CS alone and in combination with GS. GS
alone tended to diminish the ratio in a dose-dependent man-
ner. Vitamin D3 significantly decreased the expression ratio of
OPG/RANKL. Under this treatment, GS diminished the ratio,
and a statistically significant decrease was found at the high-
est concentration.
Figure 1
Levels of alkaline phosphatase and osteocalcin in human osteoarthritis subchondral bone osteoblasts Levels of alkaline phosphatase and osteocalcin in human osteoarthritis subchondral bone osteoblasts. Alkaline phosphatase activity (a) and osteo-
calcin level (b) were determined after treatment with chondroitin sulfate (CS) (200 μg/mL), glucosamine sulfate (GS) (50 or 200 μg/mL), or both 
(200 μg/mL each) in the absence or presence of vitamin D3 at 50 nM. Alkaline phosphatase activity (a) was determined in the cell lysate by sub-
strate hydrolysis using p-nitrophenylphosphate, whereas osteocalcin level (b) was determined in the culture media by using a specific enzyme immu-
noassay. Data are from eight independent experiments. Statistical significance was assessed by paired Student t test. P value indicates the 
statistical difference between control (C, basal conditions) and vitamin D3-treated specimens.Arthritis Research & Therapy    Vol 9 No 6    Tat et al.
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Figure 2
Levels of osteoprotegerin (OPG), receptor activator of nuclear factor-kappa B ligand (RANKL), and OPG/RANKL ratio in human osteoarthritis  subchondral bone osteoblasts Levels of osteoprotegerin (OPG), receptor activator of nuclear factor-kappa B ligand (RANKL), and OPG/RANKL ratio in human osteoarthritis 
subchondral bone osteoblasts. Expression and production of OPG (a), expression of RANKL (b), and expression ratio of OPG/RANKL (c) of cells 
incubated in the absence or presence of chondroitin sulfate (CS) (200 μg/mL), glucosamine sulfate (GS) (50 or 200 μg/mL), or both (200 μg/mL 
each) in the absence or presence of vitamin D3 at 50 nM. Total RNA was extracted and processed for quantitative polymerase chain reaction 
(qPCR), and the data are expressed as the mean ± standard error of the mean of arbitrary unit. The release of OPG was determined in the culture 
medium by a specific enzyme-linked immunosorbent assay. Data are from eight independent experiments. Statistical significance was assessed by 
paired Student t test versus autologous control. Underlined p value indicates the statistical difference between control (C, basal conditions) and vita-
min D3-treated specimens.Available online http://arthritis-research.com/content/9/6/R117
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Resorption activity
In our sample, the percentage of resorption in the non-treated
specimens was 16.2% ± 3.4% (n = 9). Data as illustrated in
Figure 3 showed a decrease in the resorption activity when
each compound, CS and GS (p < 0.04), was incubated alone.
The resorption activity decrease became maximal when CS
and GS were combined (p < 0.01). As expected, vitamin D3
significantly reduced this process[11]. Under vitamin D3,
although there was a tendency to further reduce the resorption
activity in the presence of GS alone or CS and GS together,
statistical significance was not reached.
The possibility that CS or GS acts directly on the osteoclast
formation process was also examined. Experiments were per-
formed as above in which only the PBMCs were inoculated in
the well, TRAP staining performed, and the level of multinucle-
ated cells determined. Data showed (n = 2) that CS or GS or
the two combined do not affect the PBMC differentiation proc-
ess: levels of 20%, 21%, 19%, and 18% were recorded for
control (untreated), CS, GS, and CS and GS, respectively.
Similar data were obtained when the PBMCs were co-cul-
tured with osteoblasts (n = 4); compared with the untreated
control specimens, which were given the value of 100%, CS
level was 105% ± 39%, GS 80% ± 34%, and CS + GS
101% ± 43%. Finally, as it has been shown in the literature
that some osteoblast lineages produce M-CSF, we investi-
gated whether CS and GS act on the osteoblasts to produce
this factor. Experiments were carried out as above (co-culture
of PBMCs and osteoblasts) in the presence or absence of M-
CSF, and the resorption activity as well as the TRAP intensity
were determined. As expected, M-CSF (n  = 4) induced
resorption (22.0% ± 6.0%) and in the absence of M-CSF (n =
3) the resorption activity was at a much lower level (2.1% ±
0.1%). Moreover, in the control (untreated) specimens and in
the absence of M-CSF, the TRAP staining level was reduced
by 25% compared with the level in the presence of M-CSF.
However, although the resorbed activity was very low without
M-CSF, CS, GS, and the two together appeared to give a pat-
tern similar to that with the presence of M-CSF, in which CS
or GS reduced the resorptive activity, and the combination of
CS and GS showed almost no resorption.
Discussion
Bone turnover is the result of a tightly balanced and coordi-
nated action of bone-resorbing and bone-forming elements.
These elements are regulated by various factors, including
cytokines, growth factors, and extracellular matrix compo-
nents. The latter include proteoglycans and GAGs such as
CS, heparan sulfate, and dermatan sulfate, which are either
associated with the cell membrane or stored in the extracellu-
lar matrix.
The recent identification of RANKL, its cognate receptor
RANK, and its decoy receptor OPG has opened a new molec-
ular field perspective on osteoclast/osteoblast biology and
bone homeostasis. We previously demonstrated that OA
subchondral bone osteoblasts can be discriminated into two
subgroups and that both OPG and RANKL expression levels,
and consequently the expression ratio of OPG/RANKL, differ
according to the metabolic state of human OA subchondral
bone osteoblasts: OPG/RANKL  is decreased in L- and
increased in H-OA osteoblasts[11]. Moreover, the previous
study[11] and that of Couchourel and colleagues[14] showed
that the metabolic state of the L-OA osteoblasts promotes
bone resorption whereas that of the H-OA favors reduced
resorption. Indeed, in L-OA osteoblasts, a higher level of differ-
entiated osteoclasts and a thinner subchondral bone mass
were observed compared with the H-OA osteoblasts[11] and
H-OA osteoblasts demonstrated a higher level of bone depo-
sition[14]. As we wanted to investigate the effects of CS and
GS on the remodelling process, we selected the L-OA
subchondral bone osteoblast subpopulation. Of note, the
osteoblasts from human subchondral bone have already been
shown to be mature differentiated cells and, as reported in the
literature[12,13,16-21], they express and produce the bone-
specific marker alkaline phosphatase, and the level of osteo-
calcin was drastically increased following vitamin D3 treat-
ment.
Figure 3
Pro-resorptive activity of human osteoarthritis subchondral bone  osteoblasts Pro-resorptive activity of human osteoarthritis subchondral bone oste-
oblasts. Resorption activity of osteoblasts co-incubated with differenti-
ated peripheral blood mononuclear cells in the presence of 
macrophage colony-stimulating factor and in the absence or presence 
of chondroitin sulfate (CS) (200 μg/mL), glucosamine sulfate (GS) 
(200 μg/mL), or both (200 μg/mL each) in the absence or presence of 
vitamin D3 at 50 nM. Data are in the absence or presence of vitamin D3 
from nine or five independent experiments, respectively. They are 
expressed as the mean resorbed surface per total surface upon treat-
ment with the factors. Statistical significance was assessed by paired 
Student t test versus autologous control. Underlined p value in\dicates 
the statistical difference between control (C, basal conditions) and vita-
min D3-treated specimens.Arthritis Research & Therapy    Vol 9 No 6    Tat et al.
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GS as well as CS have both been tested as therapeutic
agents in the treatment of OA) [27-29] Although their clinical
efficacy has been demonstrated, the mechanisms by which
they mediate their action are not yet fully known. We first exam-
ined the effect of CS and GS on alkaline phosphatase and
osteocalcin in order to evaluate whether these agents could
alter the level of bone markers of terminally differentiated oste-
oblasts. Upon treatment with CS and GS, both bone pheno-
typic cell markers were unaffected under basal conditions.
Furthermore, cells were also treated with vitamin D3, which is
known to stimulate both osteocalcin and alkaline phos-
phatase. Vitamin D3, as expected, enhanced the level of these
two bone biomarkers[16,17], but CS and GS still did not fur-
ther affect them. This strongly suggested that both com-
pounds were without effect on the cell integrity.
On the OPG and RANKL system, our data revealed that CS
can modulate the expression of these molecules by increasing
OPG and decreasing the gene expression level of RANKL,
thereby increasing the mRNA ratio of OPG/RANKL. The effect
of CS on OPG mRNA versus protein could be explained by
the following. OPG contains a heparin-binding domain to
which some GAGs were demonstrated to bind[30]. Therefore,
one can speculate that extracellular CS may bind the OPG
heparin domain, thereby enhancing OPG bioavailability by pre-
venting it from being degraded. Furthermore, extracellular
OPG was recently shown to modulate the half-life of membra-
nous RANKL by enhancing its degradation through an internal-
ization process[31].
Glucosamine is known to participate in the increased produc-
tion of GAG and proteoglycans such as aggrecan in cells[32].
Therefore, in following the aforementioned line of thought, we
expected to encounter a similar effect with the GS as with the
CS. However, the expression ratio of OPG/RANKL obtained
when cells were treated with GS was not increased. This
could be explained by the unlikelihood of modulation of extra-
cellular OPG through a direct interaction with GS, as the affin-
ity of GS, being a monosaccharide, toward OPG heparin-
binding domain is expected to be very weak. Indeed, it has
been demonstrated that even a tetrasaccharide has a very low
binding affinity toward OPG heparin domain compared with a
molecule containing more saccharides (that is, hexasaccha-
ride, octosaccharide, and decasaccharide) [30].
Nonetheless, it should not be excluded that CS and GS may
also act indirectly through the production of other factors that
in turn modulate OPG/RANKL and/or resorption activity. In
this context, explorative experiments were carried out in which
we looked at whether CS and GS affected the osteoclast dif-
ferentiation levels and/or the production of M-CSF. Data
showed no such effects with these drugs.
Recent studies reported that RANKL-independent mecha-
nisms could also be involved in orientating the bone
remodelling toward either a bone resorption or a bone forma-
tion process. Thus, one can postulate that such factors could
have been modulated by CS and/or GS, thereby indirectly
affecting bone resorption activity. Such CS- and/or GS-inde-
pendent effects could explain our findings in which, although
an increase in the OPG/RANKL ratio is found upon treatment
with CS, it appears insufficient to significantly reduce bone
resorption. The additive effect of both compounds at inhibiting
bone resorptive activity could then be explained by the sum of
the effect of CS on the OPG and RANKL and the effect of one
or both of these compounds on RANKL-independent mecha-
nisms on osteoclastogenesis.
Among the RANKL-independent mechanisms, the following
provide interesting hypotheses. Small proteoglycans such as
decorin and biglycan are composed of CS chains[8]. These
small proteoglycans are able to sequester the transforming
growth factor-beta (TGF-β) released by the OA osteoblasts
[12], thereby inhibiting the direct stimulatory effect of TGF-β
on osteoclast formation) [33-35]. Moreover, GS also demon-
strated on an articular cell, the chondrocyte, a RANKL-inde-
pendent effect on osteoclastogenesis by inhibiting the
expression of genes needed for the completion of the osteo-
clastogenesis process. Indeed, it was demonstrated that inter-
leukin-1-beta (IL-1β) mediates through a RANKL-independent
mechanism the multinucleation and the activation of osteo-
clasts[36] and that treatment with GS prevents IL-1β effects)
[37-39] GS was also shown, on chondrocytes, to directly
inhibit the activation of the transcription factor nuclear factor-
kappa B[38,39], thus preventing the activation of a gene
required for osteoclastogenesis. It should be noted that, in the
resorption assay used in the present study, cells are incubated
with the factors for as long as 3 weeks; therefore, the effect of
the drugs on growth factors, cytokines, and transcription fac-
tors could very well prevail. Hence, GS, through RANKL-inde-
pendent mechanisms, and CS, through RANKL-dependent
and -independent mechanisms, may explain the additive
reduced resorption upon treatment with these two factors.
Data showed that vitamin D3 had no effect on the OPG gene
expression and protein levels but markedly increased RANKL
and, as a result, significantly inhibited the expression ratio of
OPG/RANKL. These findings agree with the recent literature
showing that vitamin D3 acts on osteoblasts, thereby increas-
ing RANKL[40] and decreasing OPG[41,42] However, in our
study, even though vitamin D3 decreased the OPG/RANKL
ratio in favor of osteoclastogenesis, a significant decrease in
the resorptive activity was observed. This indicates that the
RANKL-induced osteoclast differentiation from the differenti-
ated PBMC/osteoblast co-culture system was significantly
inhibited by vitamin D3. The inhibition of the resorption activity
of OA osteoblasts with vitamin D3 could relate to a direct effect
of this factor on osteoclasts. Indeed, Itonaga and col-
leagues[43] showed a marked decrease in the formation of
TRAP+ and VNR+ (vitronectine receptor+) multinucleated cellsAvailable online http://arthritis-research.com/content/9/6/R117
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from PBMCs when treated with vitamin D3 and suggest that
this factor inhibits osteoclastogenesis through a direct effect
on osteoclast precursors.
There are conflicting reports in the literature on the effects of
factors, including vitamin D3, on the OPG and RANKL expres-
sion levels on bone cells) [44-46] The absence of a consensus
may be linked to the use of different experimental model sys-
tems, species (rat, mouse, human, and so on), sources of oste-
oblasts (trabecular or subchondral bone), culture conditions,
and the physiological/pathological states of cells. Most
reports are from experiments performed on cells from animals
and on trabecular bone. Moreover, Thomas and col-
leagues[47] reported that vitamin D3  regulates the OPG/
RANKL expression ratio differently, depending on the stage of
maturity of osteoblasts. Thus, the different findings in the
present study compared with some of those in the literature
could be due to the use of human specimens from patients
with OA, the fact that the osteoblasts are mature but at a par-
ticular stage of the disease, and that osteoblasts are from the
subchondral bone.
Conclusion
Our study provides new and interesting data on the effect of
C S  a n d  G S  o n  h u m a n  O A  s u bchondral bone osteoblast
metabolism. Our data indicate that these compounds, alone or
in combination, do not overly affect OA subchondral bone
cells. However, CS demonstrated a direct effect at curbing the
production of OPG and RANKL, two major factors involved in
the remodelling process, and GS significantly reduced the
resorptive activity, resulting, when both CS and GS are com-
bined, in a marked reduced resorptive activity. These findings,
in addition to the results of studies exploring the effects of
these compounds on the catabolic pathways of OA, provide
interesting and insightful information about the mechanisms by
which these drugs could exert positive effects on the OA dis-
ease process.
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